December 12 – 14 2023 | Boston, MA

Recent years have seen highly promising and rapid advances in the pre-clinical development and clinical evolution of oncolytic virotherapies. They are increasingly being recognized as a therapy with huge potential to change the landscape for cancer immunotherapy.

The global, leading, and hotly anticipated annual 8th Oncolytic Virotherapy Summit returns to Boston this December, as the industry’s definitive, and most comprehensive forum. Bringing you 29+ world-class speakers from key stakeholders from leading biopharma, this event will be showcasing brand new pivotal data to ensure a pathway of success for regulatory approval of OV drugs.

This forum will unite 80+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC), and Regulations to overcome the industry’s largest and most critical bottlenecks.

Beacon’s Oncolytic Viruses Research Lead, Megan Taylor, will be providing a drug and trial landscape analysis as well as an examination of the preclinical landscape, and what it can tell us about the potential future of OVs. This is one not to be missed.

Join the only end-to-end forum dedicated to emerging and advancing OV immunotherapies and contribute to driving the next wave of clinical approvals, towards a landscape of more effective anti-cancer drugs generating anti-tumour immune response within patients in need.